Edelmiro Reganon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edelmiro Reganon has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Virtudes Vila
Research Center, Hospital Universitario La Fe, Spain
7 shared publicationsJusto Aznar
5 shared publicationsV. Vila
4 shared publicationsV. Martínez-Sales
3 shared publicationsAmparo Vaya
2 shared publicationsAmparo Vayá
2 shared publications
Latest Publications
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 7583
Circulating endothelial cells, endothelial progenitor cells, microparticles, and markers of inflammation and coagulation in advanced non-small cell lung cancer.
7583 Background: Circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), and microparticles (MPs) have prognostic value in cancer, and might be predictors of response to chemotherapy and antiangiogenic treatments. We investigated the pre- and post-treatment levels of CECs, EPCs MPs and inflammation and coagulation markers in patients with stage IIIB and IV non-small cell lung cancer (NSCLC). Methods: We studied 60 patients, before first line taxane and platinum chemotherapy +/- bevacizumab and sixty controls. Quantification of CECs was carried out by an immunomagnetic technique. The number of EPCs (CD34/CD133/CD309) and MPs-phosphatidylserine-positive (0.5-1μm) in blood was evaluated by flow cytometry. Markers of inflammation: interleukin-6 (IL-6), coagulation: tissue factor (TF) and angiogenesis vascular endothelial growth factor (VEGF) and their receptors VEGFR1 and VEGFR2 were quantified by ELISA. Results: Mean number of CECs was significantly increased in patients before and after treatment as compared to controls p15 months (p<0.05), as well as an increased levels of IL6 and TF in stage IIIB patients (p<0.01). Conclusions: CECs, EPCs and MPs, as well as a set of markers of inflammation and coagulation, are strongly elevated in patients with advanced NSCLC and still elevated after treatment. The influence of treatment on CEC, EPC and MP levels is unclear and needs further study.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 7583
Circulating endothelial cells, endothelial progenitor cells, microparticles, and markers of inflammation and coagulation in advanced non-small cell lung cancer.
7583 Background: Circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), and microparticles (MPs) have prognostic value in cancer, and might be predictors of response to chemotherapy and antiangiogenic treatments. We investigated the pre- and post-treatment levels of CECs, EPCs MPs and inflammation and coagulation markers in patients with stage IIIB and IV non-small cell lung cancer (NSCLC). Methods: We studied 60 patients, before first line taxane and platinum chemotherapy +/- bevacizumab and sixty controls. Quantification of CECs was carried out by an immunomagnetic technique. The number of EPCs (CD34/CD133/CD309) and MPs-phosphatidylserine-positive (0.5-1μm) in blood was evaluated by flow cytometry. Markers of inflammation: interleukin-6 (IL-6), coagulation: tissue factor (TF) and angiogenesis vascular endothelial growth factor (VEGF) and their receptors VEGFR1 and VEGFR2 were quantified by ELISA. Results: Mean number of CECs was significantly increased in patients before and after treatment as compared to controls p15 months (p<0.05), as well as an increased levels of IL6 and TF in stage IIIB patients (p<0.01). Conclusions: CECs, EPCs and MPs, as well as a set of markers of inflammation and coagulation, are strongly elevated in patients with advanced NSCLC and still elevated after treatment. The influence of treatment on CEC, EPC and MP levels is unclear and needs further study.
- 1 February 2011
- Published by Elsevier in International Journal of Cardiology
- Vol. 146 (3) , 484
Corrigendum to “Inflammatory markers in stable heart failure and their relationship with functional class” Int J Cardiol 129 (2008) 388–393
- 1 February 2011
- Published by Elsevier in International Journal of Cardiology
- Vol. 146 (3) , 484
Corrigendum to “Inflammatory markers in stable heart failure and their relationship with functional class” Int J Cardiol 129 (2008) 388–393
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 2086
Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy.
2086 Background: Circulating endothelial cells (CECs) have prognostic and predictive value in breast cancer patients treated with metronomic chemotherapy. High levels of microparticles (MPs) are associated to shorter survival in prostate cancer. We investigated the pre- and posttreatment levels of CECs, MPs and several inflammation and coagulation markers in patients with newly diagnosed glioblastoma (GB) who received protracted temozolomide (PTMZ) and radiotherapy (RT). Methods: Peripheral blood was obtained from 14 patients with GB before and 4-5 weeks after beginning of treatment. Healthy subjects (n = 22) were used as controls. Isolation and quantification of CECs were determined by an immunomagnetic technique using CD146 and lectin-1 of Ulex Europaeus combined with fluorescein. Flow cytometry of plasma was used for detection of total phosphatidylserine-positive MPs, labeled with FITC-Annexin V. Endogen thrombin generation (ETG) was measured by the calibrated automated thrombogram method (CAT). Prothrombin fragment 1+2 (F1+2) and interleukin-6 (IL-6) were measured by ELISA. Results: Mean number of CECs was significantly increased in patients before (112 ± 65 cells/mL) and after treatment (122 ± 80 cell/mL) as compared to controls (10 ± 5 cell/mL; p < 0.0001). Mean number of MPs was significantly increased in patients before (794 ± 573 MPs/μ L) and after treatment (408 ± 207 MPs/μ L) as compared to controls (234 ± 174 MPs/μ L; p < 0.05). Levels of IL-6 were significantly higher in patients before and after treatment (IL6, 8.3 ± 14.3 pg/mL; 3.2 ± 3.1 pg/mL) than in controls (0.9 ± 0.8 pg/mL). Levels of coagulation markers were significantly higher in patients before treatment (F1+2, 0.33 ± 0.18 pmol/mL; ETG, 234 ± 106 nM). However, levels of both markers decreased near normal values (F1+2, 0.22 ± 0.07 vs. 0.17 ± 0.04 pmol/mL; ETG, 169 ± 146 vs. 162 ± 72 nM) after treatment. Conclusions: CECs and MPs, as well as a set of markers of inflammation and coagulation, are strongly elevated in patients with GB. Coagulation markers decrease after treatment with PTMZ+RT. The influence of treatment on CEC and MP levels is unclear and needs further study. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Schering-Plough
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 2086
Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy.
2086 Background: Circulating endothelial cells (CECs) have prognostic and predictive value in breast cancer patients treated with metronomic chemotherapy. High levels of microparticles (MPs) are associated to shorter survival in prostate cancer. We investigated the pre- and posttreatment levels of CECs, MPs and several inflammation and coagulation markers in patients with newly diagnosed glioblastoma (GB) who received protracted temozolomide (PTMZ) and radiotherapy (RT). Methods: Peripheral blood was obtained from 14 patients with GB before and 4-5 weeks after beginning of treatment. Healthy subjects (n = 22) were used as controls. Isolation and quantification of CECs were determined by an immunomagnetic technique using CD146 and lectin-1 of Ulex Europaeus combined with fluorescein. Flow cytometry of plasma was used for detection of total phosphatidylserine-positive MPs, labeled with FITC-Annexin V. Endogen thrombin generation (ETG) was measured by the calibrated automated thrombogram method (CAT). Prothrombin fragment 1+2 (F1+2) and interleukin-6 (IL-6) were measured by ELISA. Results: Mean number of CECs was significantly increased in patients before (112 ± 65 cells/mL) and after treatment (122 ± 80 cell/mL) as compared to controls (10 ± 5 cell/mL; p < 0.0001). Mean number of MPs was significantly increased in patients before (794 ± 573 MPs/μ L) and after treatment (408 ± 207 MPs/μ L) as compared to controls (234 ± 174 MPs/μ L; p < 0.05). Levels of IL-6 were significantly higher in patients before and after treatment (IL6, 8.3 ± 14.3 pg/mL; 3.2 ± 3.1 pg/mL) than in controls (0.9 ± 0.8 pg/mL). Levels of coagulation markers were significantly higher in patients before treatment (F1+2, 0.33 ± 0.18 pmol/mL; ETG, 234 ± 106 nM). However, levels of both markers decreased near normal values (F1+2, 0.22 ± 0.07 vs. 0.17 ± 0.04 pmol/mL; ETG, 169 ± 146 vs. 162 ± 72 nM) after treatment. Conclusions: CECs and MPs, as well as a set of markers of inflammation and coagulation, are strongly elevated in patients with GB. Coagulation markers decrease after treatment with PTMZ+RT. The influence of treatment on CEC and MP levels is unclear and needs further study. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Schering-Plough
- 1 January 2007
- Vol. 37 (3) , 219-27
Erythrocyte deformability in obesity measured by ektacytometric techniques.
Erythrocyte deformability (ED) has been scarcely evaluated in obese patients without other concomitant cardiovascular risk factors and contradictory results have been published regarding the influence of plasma lipids on the erythrocyte membrane lipid composition and insulin resistance on this rheological parameter. In 67 severe or morbid obese patients without other cardiovascular risk factors (51 women and 11 men, aged 34+/-11 years) and in 67 controls (45 women and 22 men, aged 32+/-10 years), ED has been determined by ektacytometric techniques in a Rheodyn SSD, the elongation index (EI) being measured at 12, 30 and 60 Pa, along with plasma lipids, red blood cell membrane lipids (cholesterol and phospholipids) and insulin resistance indexes in basal conditions and after a three month diet period. No significant differences were obtained in the EI between obese patients and the control group at any of the shear stresses tested (P>0.05). The cholesterol and phospholipid content of the red blood cell membrane did not significantly differ between cases and controls (P>0.05). Obese patients with metabolic syndrome showed lower EI at 30 and 60 Pa than those without metabolic syndrome (P=0.014 and P=0.031 respectively). Weight loss was not accompanied by any changes in these rheological parameters. Obesity itself does not seem to modify ED. However, metabolic syndrome seems to decrease ED, possibly through insulin resistance.
- 1 January 2007
- Vol. 37 (3) , 219-27
Erythrocyte deformability in obesity measured by ektacytometric techniques.
Erythrocyte deformability (ED) has been scarcely evaluated in obese patients without other concomitant cardiovascular risk factors and contradictory results have been published regarding the influence of plasma lipids on the erythrocyte membrane lipid composition and insulin resistance on this rheological parameter. In 67 severe or morbid obese patients without other cardiovascular risk factors (51 women and 11 men, aged 34+/-11 years) and in 67 controls (45 women and 22 men, aged 32+/-10 years), ED has been determined by ektacytometric techniques in a Rheodyn SSD, the elongation index (EI) being measured at 12, 30 and 60 Pa, along with plasma lipids, red blood cell membrane lipids (cholesterol and phospholipids) and insulin resistance indexes in basal conditions and after a three month diet period. No significant differences were obtained in the EI between obese patients and the control group at any of the shear stresses tested (P>0.05). The cholesterol and phospholipid content of the red blood cell membrane did not significantly differ between cases and controls (P>0.05). Obese patients with metabolic syndrome showed lower EI at 30 and 60 Pa than those without metabolic syndrome (P=0.014 and P=0.031 respectively). Weight loss was not accompanied by any changes in these rheological parameters. Obesity itself does not seem to modify ED. However, metabolic syndrome seems to decrease ED, possibly through insulin resistance.
- 1 January 2007
- Published by Elsevier in Thrombosis Research
- Vol. 119 (1) , 73-78
Sialic acid is an inflammation marker associated with a history of deep vein thrombosis
- 1 January 2007
- Published by Elsevier in Thrombosis Research
- Vol. 119 (1) , 73-78
Sialic acid is an inflammation marker associated with a history of deep vein thrombosis
- 31 December 2005
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 17 (6) , 277-282
La atorvastaina modula a la trombospondina en células endoteliales umbilicales humanas
- 31 December 2005
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 17 (6) , 277-282
La atorvastaina modula a la trombospondina en células endoteliales umbilicales humanas
- 1 July 2003
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 1, P0510
Endothelial and angiogenesis activity in terminal heart failure and heart-transplant patients: a prospective study
- 1 July 2003
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 1, P0510
Endothelial and angiogenesis activity in terminal heart failure and heart-transplant patients: a prospective study
- 1 January 2003
- Published by Elsevier in Thrombosis Research
- Vol. 112 (4) , 217-221
Association between inflammation and hemostatic markers in atherothrombotic stroke
- 1 January 2003
- Published by Elsevier in Thrombosis Research
- Vol. 112 (4) , 217-221
Association between inflammation and hemostatic markers in atherothrombotic stroke
- 1 July 2002
- Vol. 87 (7) , 740
Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.
It has been reported that the influence of plasma fibrinogen on the incidence of myocardial infarction is related to inflammatory processes. The aim of this study was to investigate the relationship between inflammatory activity, fibrinogen and thrombin generation in patients 5 years after the acute phase of myocardial infarction. Sixty-seven patients 5 years after a myocardial infarction and 67 control subjects were studied. Plasma fibrinogen protein (Fg-protein) and function (Fg-function), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), total sialic acid (TSA) and C-reactive protein (CRP) were measured. The levels of Fg-protein, Fg-function, F1+2, TAT, TSA and CRP were significantly higher in patients than in the control subjects. Plasma TSA correlated with CRP (r=0.31, p<0.05). There was a significant correlation between TSA and Fg-protein or Fg-function (r=0.48, p<0.01). CRP correlated with Fg-function (r=0.32, p<0.05) while there was no correlation between CRP and Fg-protein. CRP also correlated with F1+2 and TAT (r= 0.4, p<0.01). Five years after myocardial infarction there was clear evidence of low-grade inflammation that was accompanied by an increase in thrombin formation. The increase of the plasma fibrinogen level is mainly related to TSA and the increase of CRP, which is associated with thrombin generation.
- 1 July 2002
- Vol. 87 (7) , 740
Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.
It has been reported that the influence of plasma fibrinogen on the incidence of myocardial infarction is related to inflammatory processes. The aim of this study was to investigate the relationship between inflammatory activity, fibrinogen and thrombin generation in patients 5 years after the acute phase of myocardial infarction. Sixty-seven patients 5 years after a myocardial infarction and 67 control subjects were studied. Plasma fibrinogen protein (Fg-protein) and function (Fg-function), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), total sialic acid (TSA) and C-reactive protein (CRP) were measured. The levels of Fg-protein, Fg-function, F1+2, TAT, TSA and CRP were significantly higher in patients than in the control subjects. Plasma TSA correlated with CRP (r=0.31, p<0.05). There was a significant correlation between TSA and Fg-protein or Fg-function (r=0.48, p<0.01). CRP correlated with Fg-function (r=0.32, p<0.05) while there was no correlation between CRP and Fg-protein. CRP also correlated with F1+2 and TAT (r= 0.4, p<0.01). Five years after myocardial infarction there was clear evidence of low-grade inflammation that was accompanied by an increase in thrombin formation. The increase of the plasma fibrinogen level is mainly related to TSA and the increase of CRP, which is associated with thrombin generation.